Search Bar & Filters
Found 61 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness and safety of elenestinib BLU-263 combined with symptom directed therapy SDT compared to placebo plus SDT in adults with indolent systemic mastocytosis ISM whose symptoms are not well controlled by SDT alone. This Phase 23 randomized, double-blind, placebo-controlled study includes participants from Parts 1 and 2 with ISM, with those in Part 2 continuing into Part 3 for open-label elenestinib treatment. Part K enrolls participants with prior use of selective KIT inhibitors, and additional pharmacokinetic groups will also participate. Participants receive SDT tailored individually and take either oral elenestinib or matching placebo once daily. In Part 1, treatment continues until study completion, while Part 2 involves approximately 48 weeks of dosing. Part 3 and other parts may extend treatment up to about 5 years. The study monitors participants throughout these periods, with dosing and symptom management adjusted as needed. During the study, participants undergo various assessments including symptom scoring with the Indolent Systemic Mastocytosis-Symptom Assessment Form ISM-SAF, safety monitoring for adverse events, and laboratory tests such as serum tryptase levels and KIT D816V allele fraction. Bone marrow mast cells, bone mineral density, and quality of life measures are also evaluated. Researchers track these outcomes at multiple timepoints from baseline up to 5 years to understand treatment impact and participant safety.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the ability of MammoWave, an innovative microwave mammogram device, to detect breast lesions in women. This investigation is multicentric, prospective, single-arm, and stratified by breast density. MammoWave uses very low power microwaves instead of traditional x-rays, making it safe for use at any age, including during pregnancy, and allows repeated exams without ionizing radiation exposure. The study aims to confirm MammoWaves effectiveness in detecting both malignant and benign breast lesions, including palpable, non-palpable, and microcalcifications. The study will enroll up to 600 participants across several centers in Italy, Germany, and Spain. It includes two phases a preliminary phase to optimize the imaging algorithm by examining volunteers without lesions, followed by the main phase enrolling women with and without breast lesions. All participants will undergo the MammoWave exam while lying prone on the device, which takes about 10 minutes per breast. The exam includes image acquisition and data processing to generate images and parameters describing breast tissue. Participants will have a standard breast screening alongside the MammoWave exam. Researchers will assess MammoWaves sensitivity and specificity compared to standard diagnostic methods, including mammography, ultrasound, and MRI. Patient satisfaction will also be measured through questionnaires. The primary outcome is the number of true positive results during the MammoWave procedure. The study began in January 2023 and is expected to continue until January 2027, with ongoing monitoring and comparison of results.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating MammoWave, a device that uses low-power microwaves instead of X-rays, for early breast cancer detection in women aged 45 to 74. This prospective, multicenter clinical investigation aims to confirm that MammoWave achieves sensitivity greater than 75% and specificity greater than 90% for breast cancer detection among 10,000 volunteers undergoing regular screening programs. The study compares MammoWave results with conventional breast examination methods including mammograms and other radiological or histological tests. Participants will undergo both the standard breast screening exams and the MammoWave exam. The MammoWave exam involves lying prone on a bed while the device collects microwave data from both breasts over about 8 minutes. Data processing uses a special imaging algorithm to produce microwave images and classification results indicating suspicious or non-suspicious findings. The study device contains the same hardware as a CE-marked version but uses updated software. During the study, participants will have conventional breast exams along with the MammoWave exam. Researchers will evaluate MammoWaves sensitivity and specificity during the procedure and analyze detection rates, recall rates, and positive predictive values at baseline. Volunteers will also complete satisfaction questionnaires. The study will monitor breast cancer detection by histological type, size, and breast density. The trial is expected to run until December 2026.
Actively Recruiting
Researchers are evaluating ELVN-001, an investigational drug, in adults with chronic myeloid leukemia CML, including those with a specific T315I mutation. This early-phase trial aims to find safe and tolerable doses for further study, especially in patients who have relapsed, are resistant, or cannot tolerate current tyrosine kinase inhibitors TKIs. The study also examines how ELVN-001 affects disease markers and its overall safety profile. The trial includes a dose escalation phase to identify recommended doses, followed by dose expansion phases that treat patients with or without the T315I mutation at those doses. ELVN-001 is given orally once or twice daily. Participants receive the drug as a single agent, and the study monitors responses and safety during these phases. Participants will undergo regular assessments including monitoring for side effects, laboratory tests, heart evaluations, and measurement of molecular responses related to CML over periods ranging from 28 days up to 3 years. The study tracks drug levels in the body for up to 6 months and evaluates long-term outcomes such as complete blood responses. Overall participation duration varies, with close safety follow-up throughout.
Actively Recruiting
Researchers are evaluating the combination of camizestrant and ribociclib in patients with estrogen receptor-positive ER, human epidermal growth factor receptor 2-negative HER2- advanced breast cancer who have not previously received systemic treatment for their advanced disease. This Phase IIIb, global, multicenter, single-arm study aims to assess the effectiveness, safety, and tolerability of this treatment approach. Participants will receive daily oral doses of camizestrant at 75 mg and ribociclib at 600 mg. All enrolled patients will take these medications until they decide to stop treatment or for any other reason that leads to discontinuation. The study does not involve comparison groups but monitors treatment outcomes in all participants receiving the combination. During the study, participants will undergo evaluations to monitor how long they remain on treatment before starting another therapy or experiencing progression. Researchers will assess treatment safety, including any significant side effects occurring within the first six months. Participants will have regular visits to assess their health status and treatment response. The total study duration extends up to two years following the first dose of treatment.
Actively Recruiting
Researchers are conducting a prospective, multicenter observational study to create a registry for patients diagnosed with unresectable locally advanced or metastatic breast cancer, either after recurrence or as a first diagnosis since January 2016. This study aims to understand the distribution of different breast cancer subtypes and patient characteristics over an 8-year period. No specific treatment is assigned by the study, and clinical decisions are made independently by the treating physicians. Participants are grouped based on breast cancer subtypes characterized by receptors such as Estrogen receptor ER, Progesterone receptor PgR, HER2, and Ki-67 expression levels. The study does not intervene in treatment instead, it observes patients receiving standard care as decided by their doctors. Patients may include males and females, and there is no age upper limit. Data collection includes patient and tumor characteristics, biomarker presence in tumor and blood samples, and the impact of surgery timing on patients initially diagnosed with metastatic disease. During the study, participants medical records and disease management data are accessed for analysis. Researchers collect information over 8 years, including subtype distribution, heredofamilial risk, gender differences in disease progression, and biomarker frequency. Patients can withdraw consent at any time, and the treating clinician is encouraged to follow patients until death or study completion. The studys primary outcome is the number of patients with various breast cancer subtypes, with several secondary outcomes related to disease characteristics and treatment timing.
Actively Recruiting
Researchers are evaluating camizestrant compared to standard endocrine therapy in patients with ER-positive, HER2-negative early breast cancer who have an intermediate or high risk of disease recurrence. This Phase III open-label study includes patients who have completed definitive locoregional therapy, with or without chemotherapy, and have received standard adjuvant endocrine therapy for at least 2 years and up to 5 years. The study aims to determine if camizestrant improves invasive breast cancer-free survival and other important outcomes over a long-term follow-up. Participants will be randomly assigned to receive either camizestrant orally or continue standard endocrine therapy chosen by their doctor, which may include aromatase inhibitors like exemestane, letrozole, anastrozole, or tamoxifen. Treatment in both groups will last for up to 60 months. The study allows prior use of CDK46 inhibitors and includes an open-label design where both participants and researchers know the assigned treatment. During the study, participants will be monitored with assessments including survival outcomes, disease-free survival, relapse-free survival, and overall survival for up to 10 years from the last patient randomized. Safety will be tracked through adverse event reporting, laboratory and vital signs tests, and symptom questionnaires measuring arthralgia, hot flushes, vaginal dryness, and quality of life. Pharmacokinetics will be studied up to 6 months after treatment starts. The total duration of participation can extend over many years to capture long-term results.
Actively Recruiting
Researchers are evaluating the safety, tolerability, and effects of ROC-101 in adults diagnosed with Pulmonary Arterial Hypertension PAH or Pulmonary Hypertension associated with Interstitial Lung Disease ILD-PH. This Phase 2a, open-label, single-arm exploratory study includes participants classified under World Health Organization WHO Group I PAH or Group III ILD-PH, aiming to assess oral doses of ROC-101 alongside standard care. Participants will receive oral ROC-101 daily, starting at 10 mg and gradually increasing to 40 mg for a 24-week treatment period, combined with standard of care therapy. After this period, participants may continue in a long-term extension phase until the study program concludes or regulatory approval is granted. Evaluations include hemodynamic measurements obtained through right heart catheterization and monitoring of adverse events. Throughout the study, participants will undergo assessments such as pulmonary function tests, exercise capacity tests 6-minute walk distance, and right heart catheterization measurements at baseline and 24 weeks. Researchers will track changes in pulmonary vascular resistance and safety outcomes, along with various cardiac and respiratory function parameters. The total study duration includes the initial 24-week treatment phase followed by an optional long-term extension period for continued monitoring.
Actively Recruiting
Advanced Parkinsons disease is a neurological condition characterized by symptoms such as tremors, stiffness, and slowed movements. This observational study evaluates changes in sleep disturbances in adults with advanced Parkinsons disease who are receiving subcutaneous FoslevodopaFoscarbidopa. The study is conducted under routine clinical practice with approximately 103 adult participants across about 20 sites in Spain. Participants will be treated with FoslevodopaFoscarbidopa delivered via subcutaneous infusion as prescribed by their doctors according to the local label. The study involves no additional treatment burden and follows participants for up to 12 weeks while they continue their prescribed therapy. During the study, participants will attend regular hospital or clinic visits aligned with their standard clinical care. Researchers will assess changes in Parkinsons disease-related sleep disturbances using the Parkinsons Disease Sleep Scale - 2 PDSS-2 over approximately 12 weeks. The study monitors participants without altering their routine treatment and collects data on sleep disturbances and other relevant health outcomes.
Actively Recruiting
Researchers are studying an experimental drug called odronextamab combined with chemotherapy in patients with Diffuse Large B-cell Lymphoma DLBCL. This includes adults with untreated DLBCL as well as those whose disease has returned or not responded to treatment. The study aims to evaluate the safety, dosing, and effectiveness of odronextamab plus chemotherapy compared to the current standard treatment, rituximab combined with chemotherapy. The study is divided into Part 1A and 1B, which focus on determining safe doses and schedules of odronextamab combined with chemotherapy drugs including cyclophosphamide, doxorubicin, vincristine, and prednisone or prednisolone. Part 2 is a randomized comparison where participants receive either odronextamab plus chemotherapy or rituximab plus chemotherapy. Odronextamab and rituximab are given by intravenous infusion, with rituximab also possibly given subcutaneously. Participants will be monitored for side effects, disease progression, and quality of life over time. Assessments include measuring drug levels in the blood, immune response to the drug, and physical functioning questionnaires. The study will follow participants for up to five years to evaluate progression-free survival and other outcomes. Safety and adverse events will be tracked for up to two years.
1-10 of 61
1